[go: up one dir, main page]

WO1999046368A3 - Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment - Google Patents

Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment Download PDF

Info

Publication number
WO1999046368A3
WO1999046368A3 PCT/US1999/005722 US9905722W WO9946368A3 WO 1999046368 A3 WO1999046368 A3 WO 1999046368A3 US 9905722 W US9905722 W US 9905722W WO 9946368 A3 WO9946368 A3 WO 9946368A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbohydrate
active
present
active enzymes
cdna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/005722
Other languages
French (fr)
Other versions
WO1999046368A2 (en
Inventor
John C Klock
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomarin Pharmaceutical Inc
Original Assignee
Biomarin Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharmaceutical Inc filed Critical Biomarin Pharmaceutical Inc
Priority to AU30068/99A priority Critical patent/AU3006899A/en
Publication of WO1999046368A2 publication Critical patent/WO1999046368A2/en
Publication of WO1999046368A3 publication Critical patent/WO1999046368A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405Glucanases
    • C12N9/2408Glucanases acting on alpha -1,4-glucosidic bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/47Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88Lyases (4.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The present invention features a method for treating wounds comprising the step of administering an effective amount of a carbohydrate-active enzyme. In another aspect, the present invention features pharmaceutical compositions for treating wounds. The invention also features cDNA sequences for carbohydrate-active enzymes and cDNA expression systems for using various DNA sequences to produce mammalian carbohydrate-active enzymes for a variety of uses. The invention further includes recombinant plasmids comprising the cDNA of mammalian carbohydrate-active enzymes. The invention also includes transformed cells comprising a heterologous DNA sequence that encodes for a carbohydrate-active enzyme or a biologically active fragment or mutant thereof. Preferred carbohydrate-active enzymes according to the present invention include chondroitinases and hyaluronidases.
PCT/US1999/005722 1998-03-13 1999-03-12 Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment Ceased WO1999046368A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU30068/99A AU3006899A (en) 1998-03-13 1999-03-12 Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3906698A 1998-03-13 1998-03-13
US09/039,066 1998-03-13

Publications (2)

Publication Number Publication Date
WO1999046368A2 WO1999046368A2 (en) 1999-09-16
WO1999046368A3 true WO1999046368A3 (en) 2000-08-31

Family

ID=21903486

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005722 Ceased WO1999046368A2 (en) 1998-03-13 1999-03-12 Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment

Country Status (2)

Country Link
AU (1) AU3006899A (en)
WO (1) WO1999046368A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003304173A1 (en) 2002-05-04 2005-01-04 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US6762836B2 (en) 2002-05-22 2004-07-13 General Electric Company Portable laser plasma spectroscopy apparatus and method for in situ identification of deposits
WO2004092361A1 (en) * 2003-04-15 2004-10-28 Ista Pharmaceuticals, Inc. Process for isolating and purifing ovine hyaluronidase
EP2353606B1 (en) * 2003-05-16 2013-04-17 Acorda Therapeutics, Inc. Compositions and methods for the treatment of CNS injuries
ES2616749T3 (en) 2003-05-16 2017-06-14 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for CNS treatment
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
JP4926962B2 (en) 2004-05-18 2012-05-09 アコーダ セラピューティクス、インク. Purification method of chondroitinase and its stable preparation
EP1928490B8 (en) 2005-09-26 2012-10-03 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
CA2666536C (en) 2006-10-10 2018-08-07 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US20160101166A1 (en) 2014-10-10 2016-04-14 Rochal Industries, Llp Compositions and kits for treating pruritus and methods of using the same
US10238719B2 (en) 2014-10-10 2019-03-26 Rochal Industries, Llc Compositions and kits for enzymatic debridement and methods of using the same
US9592280B2 (en) 2014-10-10 2017-03-14 Rochal Industries Llc Compositions and kits for enzymatic debridement and methods of using the same
WO2018157011A1 (en) * 2017-02-24 2018-08-30 Xenotherapeutics, Inc. Products and methods for treating burn wounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1067253A (en) * 1965-02-15 1967-05-03 Biorex Laboratories Ltd Process for the preparation of enzymes
RO102703A2 (en) * 1988-10-05 1991-09-09 Intreprinderea De Medicamente "Biofarm", Bucuresti, Ro Producing method of a composition with hyaluronidase activity
WO1996001648A1 (en) * 1994-07-08 1996-01-25 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1067253A (en) * 1965-02-15 1967-05-03 Biorex Laboratories Ltd Process for the preparation of enzymes
RO102703A2 (en) * 1988-10-05 1991-09-09 Intreprinderea De Medicamente "Biofarm", Bucuresti, Ro Producing method of a composition with hyaluronidase activity
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
WO1996001648A1 (en) * 1994-07-08 1996-01-25 Ibex Technologies R And D, Inc. Attenuation of wound healing processes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 9319, Derwent World Patents Index; Class B04, AN 1993-157093, XP002116910 *

Also Published As

Publication number Publication date
AU3006899A (en) 1999-09-27
WO1999046368A2 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
WO1999046368A3 (en) Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
AU1916899A (en) Alpha-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
ATE393831T1 (en) COMPOSITION FOR THE IN VIVO GENERATION OF THERAPEUTIC PRODUCTS
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
CA2253287A1 (en) A process for producing a recombinant polypeptide involving the addition of an inhibitor of metal-dependent proteases or chymotrypsins to the cell culture medium
DE69733881D1 (en) Plastidtransformation in arabidopsis thaliana
IL189572A0 (en) An isolated antibody that binds a vascular endothelial cell growth factor-e (vegf-e) polypeptide and use thereof for the preparation of and as medicaments for inhibiting or preventing growth of cancer cells or angiogenesis, method using it and an article of manufacture containing it
MXPA02000877A (en) Cartilage or bone matrix as a nucleic acid delivery vehicle.
DE3682891D1 (en) TISSUE PLASMINOGEN ACTIVATOR MUTANT, THEREFORE ENCODING RECOMBINANT GENETIC INFORMATION AND METHOD FOR THE PRODUCTION OF THESE MUTANTS, THEIR USE AND PHARMACEUTICAL COMPOSITIONS.
WO2000073764A3 (en) Composition and methods for the therapeutic use of an atonal-associated sequence
CA2341276A1 (en) Human anti-factor ix/ixa antibodies
ATE368455T1 (en) USE OF (+)-TRAMADOL, O-DEMETHYLTRAMADOL, O-DESMETHYL-N-MONO-DESMETHYL-TRAMADOL FOR THE THERAPY OF URINARY INCONTINENCE
CA2234263A1 (en) Pharmaceutical composition for treating papillomavirus tumours and infection
AU6105996A (en) Replacement therapy for dental caries
AU6028898A (en) Methods for cultivating cells and propagating viruses
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
EP0388906A3 (en) Genetically engineered human cholinesterases
MX9606610A (en) INCREASED PRODUCTION OF 'beta'-GALACTOSIDASE IN ASPERGILLUS ORYZAE.
SE9501472D0 (en) Truncated IGF-I
DE59712235D1 (en) IMMUNOLOGICALLY ACTIVE PROTEINS OF BORRELIA BURGDORFERI, CODING NUCLEIC ACIDS, AND THEIR USE IN TEST KITS AND AS VACCINES
AUPQ347199A0 (en) Novel polypeptide fragments
DE3883315D1 (en) NEW FIBRINOLYTIC ENZYMS.
AU8811298A (en) Novel peptides and polypeptides useful for regenerating the nervous system
AUPM772494A0 (en) Improvements in production of proteins in host cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase